(1 - 6 von 27
)
European collaboration begins development of antibody-based senolytics
www.manufacturingchemist.com
Christoph Antz, Managing Director of Velabs, explained that the agreement will allow the development a completely new treatment against ...
G-protein-coupled receptor-specific functional antibody ...www.pathologyinpractice.com › g-...
www.pathologyinpractice.com
... start of a joint development on functional GPCR antibodies,” said Christoph Antz (Managing Director, Velabs). “Chiome's decision to continue ...
Velabs and Chiome team up to discover GPCR antibodieswww.manufacturingchemist.com › article_page
www.manufacturingchemist.com
Christoph Antz, Managing Director of Velabs, said that this agreement represents an important deal for Velabs, who target clinical applications ...
newarticle – Boersengefluester
www.boersengefluester.de
Dr. Christoph Antz, Managing Director of Velabs, states: "We are pleased to have entered this licence agreement with alytas, which will allow us to develop a ...
sortiert nach Relevanz / Datum